Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Expanded Access to Elezanumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04278235
Expanded Access Status : Available
First Posted : February 20, 2020
Last Update Posted : March 24, 2022
Information provided by (Responsible Party):

Brief Summary:
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Condition or disease Intervention/treatment
Acute Spinal Cord Injury (SCI) Acute Ischemic Stroke Drug: Elezanumab

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients, Intermediate-size Population
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access to Elezanumab

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Elezanumab
    Solution for intravenous (IV) infusion
    Other Name: ABT-555

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The participant must not be eligible for an elezanumab clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04278235

Layout table for location contacts
Contact: ABBVIE CALL CENTER 844-663-3742

Sponsors and Collaborators
Layout table for investigator information
Study Director: ABBVIE INC. AbbVie
Layout table for additonal information
Responsible Party: AbbVie Identifier: NCT04278235    
Other Study ID Numbers: C20-203
C20-284 ( Other Grant/Funding Number: AbbVie )
C20-285 ( Other Grant/Funding Number: AbbVie )
First Posted: February 20, 2020    Key Record Dates
Last Update Posted: March 24, 2022
Last Verified: March 2022
Keywords provided by AbbVie:
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Ischemic Stroke
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Cerebrovascular Disorders
Brain Diseases
Vascular Diseases
Cardiovascular Diseases